Researchers find diabetes drug extends health and lifespan in mice

Tuesday, August 6, 2013

Washington: Long-term treatment with the type 2 diabetes drug metformin improves health and longevity of male mice when started at middle age, reports an international team of scientists led by researchers at the National Institute on Aging (NIA), part of the National Institutes of Health.

Rafael de Cabo

Rafael de Cabo

The study, which tested two doses of the drug in the male mice, found the higher dose to be toxic in the animals. Scientists emphasized that considerably more research is needed before the implications of metformin for healthy aging are known for humans.

The study, headed by Rafael de Cabo of the NIA’s Intramural Research Programme, is published in Nature Communications.

“There is increasing interest in exploring how drugs for one use might be repurposed for another,” said Richard J Hodes, director of the NIA. “It is exciting to discover that a drug already known to be safe and effective in humans might be further studied for a possible, alternate use for healthy aging.”

Prescribed since the 1960s to treat type 2 diabetes, metformin is known to enhance insulin sensitivity, prompt sugar to be converted to energy, and prevent sugar build up in the liver. It also reduces risk of health issues associated with metabolic syndrome, a condition characterized by an increased chance for heart disease and stroke, as well as type 2 diabetes.

“Aging is a driving force behind metabolic syndrome and diabetes. Given that metformin is clinically proven to alleviate symptoms of these conditions, and reduce risk of cancer, we thought perhaps it was a good candidate to study for its broader effects on health and lifespan,” said de Cabo.

Specifically, de Cabo’s research focuses on testing compounds that might mimic benefits of calorie restriction, as shown in some animal models. A significant reduction in calories causes the body to adjust how it creates and processes energy, generating a mild biological stress, which contributes to the reported health benefits. Metformin works, at least in part, by also controlling the body’s energy use and production. The study offers evidence that metformin might provide some of the positive effects of calorie restriction.

In this study, researchers found male mice on a 0.1 per cent metformin treatment had a 5.83 per cent increase in lifespan compared to control group mice on a standard diet with no metformin. The 1 per cent metformin treatment had the opposite effect. These mice had a 14.4 per cent shorter lifespan compared to the control group, likely due to kidney failure. The lower metformin dose did not seem to cause any negative effect on the renal system.

A battery of tests performed with male mice taking 0.1 per cent, 1 per cent, or no metformin starting at middle age, revealed a clear health benefit of the 0.1 per cent treatment. These mice had improved general fitness and weighed less than the control group mice, despite consuming more calories. Metformin increased their use of fat for energy. Mice on metformin tended to preserve body weight with age, a characteristic associated with increased survival in other studies. They had a lower incidence of cataracts, a common health problem in the strain of mouse. Not surprisingly, metformin prevented the onset of metabolic syndrome. It had similar effects as calorie restriction on genes in the liver and muscles, which induced longevity-associated activity in the mice. Metformin also appeared to have some antioxidant effects in the mice.

A number of compounds are being tested for their possible applications to improving health with aging. A previous study by de Cabo and colleagues found that resveratrol, present in foods like grapes and nuts, improved a number of health measures in mice, but perhaps not their longevity.

The NIA-sponsored Interventions Testing Programme has studied the effects of several compounds, including metformin, resveratrol, and the immunosuppressant rapamycin, in mice. The initiative found that rapamycin extended lifespan even when fed to the mice beginning at early-old age and is looking more closely at its possible health benefits. Learning more about these and other compounds and the mechanisms underlying their effects on the body, may point the way to future aging therapies in humans, according to the researchers.

Metformin for the study was supplied by the Spanish generic manufacturer Farmhispania SA.

Categories: Medicine, RESEARCH

Tags: , , , , , ,

  More from Medicine

Safety concerns linger for generic oncology drugs in developing countries


Pharmaceutical industry-sponsored meals associated with higher prescribing rates


Researchers combine drugs to develop a new treatment for human parainfluenza virus


Common painkillers are more dangerous than we think


Stronger evidence found for link between prenatal exposure to paracetamol and the risk of developing asthma


US scientists document trajectory of Zika virus for first time

Comments »

No comments yet.

Name (required)
E-mail (required - never shown publicly)
URI
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> in your comment.